GLP-1 medicines have pushed peptide therapies into the mainstream. The next question is whether that success can extend into a broader generation of peptide drugs targeting more complex diseases. Research is already moving in that direction.
Developers are exploring peptides that act on multiple receptors or target specific biological pathways linked to metabolism, inflammation, behaviour and brain function. This creates a wider development opportunity, but it also raises the clinical risk.
A 2026 systematic review and meta-analysis covering 82 studies found potentially relevant signals in areas including Parkinson’s disease and binge eating. The findings support further research, but they do not establish that peptide therapies are effective in these conditions.
Recent Alzheimer’s results underline that point. Phase 3 EVOKE and EVOKE+ trials reported in 2026 found that oral semaglutide did not slow clinical progression in people with early Alzheimer’s disease. That outcome shows why the next phase of peptide development cannot rely on biological logic alone. A credible mechanism does not guarantee clinical success.
The opportunity therefore lies in more precise drug design. Rather than extending existing GLP-1 medicines into unrelated indications, developers are increasingly focused on building peptides around specific disease pathways. That could include multi-receptor drugs or molecules designed to produce more selective effects.
Potential targets include appetite, reward, addiction, inflammation, cognition and neurodegeneration.
If peptide platforms can address several biological systems with greater precision, they could support larger pipelines across multiple therapeutic areas. But value will depend on whether those programmes can generate clear clinical benefits.
Patient selection will also matter. Complex diseases are unlikely to respond uniformly, so identifying the right biological profile and the right patient group could become central to development strategy.
The same applies to endpoints. Traditional clinical measures remain important, but developers may also need to show changes in daily function, behaviour, cognition and quality of life.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
